Interstitial lung disease: Difference between revisions
Jump to navigation
Jump to search
Line 54: | Line 54: | ||
==Pathophysiology== | ==Pathophysiology== | ||
<div style="text-align: center;">'''Algorithm showing pathophysiology of Interstitial Lung Disease'''</div> | |||
{{Family tree/start}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | T01 | | | | | | | | | | | | T01=[[Tissue]] injury in [[lungs]]}} | |||
{{Family tree| | | | | | | | | | | | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | S01 | | | | | | | | | | S02 | | | | | | | S01=[[Parenchymal]] injury|S02=[[Vascular]] injury}} | |||
{{Family tree| | | | | | | | | | | | | | | | | |!| | | | | | | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | | | | | | R01 | | | | | | | |!| | | | | | | | | | | R02 | | | | | | | R01=[[Mast cell]]s in [[lungs]] in response to tissue injury|R02= LPA6, LPA2, and LPA4 receptors }} | |||
{{Family tree| | | | | | |,|-|^|-|.| | | | | | |!| | | | | | | | | |,|-|^|-|.| | | | | | }} | |||
{{Family tree| | Q01 | | Q06 | | Q03 | | | | | Q02 | | | | | | | | Q04 | | Q05 | | | | | Q01=Decreased [[Secreted frizzled-related protein 1|sFRP-1 (secreted frizzled-related protein 1)]] in [[fibroblasts]]|Q02= [[Insulin-like growth factor]] ([[IGF]]) signalling|Q03=[[Transforming growth factor-β]] ([[TGF-β]])|Q04= Reduced expression of angiogenic factors,<br>[[vascular endothelial growth factor]] (VEGF)|Q05=Elevation of angiostatic factors,<br>pigment epithelium-derived factor|Q06=Secretes [[tryptase]]}} | |||
{{Family tree| | |!| | | |!| | | |!| | | |,|-|-|^|-|-|.| | | | | | |`|-|v|-|'| | | | | | }} | |||
{{Family tree| | P01 | | P02 | | P05 | | P04 | | | | P03 |.| | | | | | P06 | | | | | P01=[[Wnt signaling pathway|Wnt/β-catenin signalling pathway]]|P02=PAR-2/protein kinase (PK)C-α/Raf-1/p44/42 signaling pathway|P03=[[IGFBP3|IGF-binding protein 3 (IGFBP-3]])|P04=[[Insulin-like growth factor binding protein|IGF-binding protein 5 (IGFBP-5)]]|P05=Upregulation of Egr-1 (early growth response protein 1)|P06=Loss of [[endothelial]] barrier function }} | |||
{{Family tree| |!| |!| | |!| | | |!| | | |!| | | | | |!| |!| | | | | | |!| | | | | | | | }} | |||
{{Family tree| O01 |!| | |!| | | |`|-|-|-|^|.| | | | |!| O02 | | | | | |!| | | | | | | | O01=Dysregulation of repair in [[lung tissue]] and activation of [[fibroblasts]]|O02=Regulates [[transforming growth factor-β]] ([[TGF-β]]) }} | |||
{{Family tree| | | |!| | |!| | | | | | | | |!| | | | |!|,|'| | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | |!| | |!| | | | | | | | |!| | | | A02 | | | | | | | |!| | | | | | | | A01=|A02=Induction of [[syndecan-2|syndecan-2 (SDC2)]]}} | |||
{{Family tree| | | |!| | |!| | | | | | | | |!| | | | |!| | | | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | |!| | |`|-|-|-|-|-|-|-|.|!|,|-|-|-|'| | | | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | |`|-|-|-|-|-|-|-|-|-|-| B01 | | | | | | | | | | | | |!| | | | | | | | B01=Activation,proliferation, and migration of [[fibroblast]] to the site of injury}} | |||
{{Family tree| | | | | | | | | | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | C01 | | | | | | | | | | | | |!| | | | | | | | C01=[[Fibroblasts]]}} | |||
{{Family tree| | | | | | | | | | | | |,|-|-|+|-|-|.| | | | | | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | D01 | |!| | D02 | | | | | | | | | |!| | | | | | | | D01=Altered PTEN (phosphatase and tensin homologue)/Akt axis|D02=Acquire contractile stress fibres}} | |||
{{Family tree| | | | | | | | | | | | |!| | |!| | |!| | | | | | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | G01 | |!| | G02 | | G03 | | | | | |!| | | | | | | | G01= Inactivates [[FOX proteins|Fox (forkhead box) O3a]]|G02=Protomyofibroblast, composed of cytoplasmic [[actins]]|G03=[[Pleural]] [[mesothelial]] cells (PMCs)}} | |||
{{Family tree| | | | | | | | | | | | |!| | |!| | |!| | | |!| | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | H01 | |!| | H02 | | H03 | | | | | |!| | | | | | | | H01= Downregulation of [[Caveolin 1|caveolin-1 (cav-1)]] and Fas expression|H02=De novo expression of α-smooth muscle actin (α-SMA)|H03=TGF-β1-dependent mesothelial–mesenchymal transition}} | |||
{{Family tree| | | | | | | | | | | | |!| | |!| | | |!| |!| | | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | I01 | |!| | | | I02 | | | | | | | |!| | | | | | | | I01=[[Fibroblast]] resistant to [[apoptosis]]|I02=[[Myofibroblasts]]}} | |||
{{Family tree| | | | | | | | | | | | | | | |!| | | |!| |!| | | | | | | |!| | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | |!| | | |!| |)|-|-|-|-|.| | |!| | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | |!| | | |!| J02 | | | J03 | |!| | | | | | | | J02=Different ranges of contractions mediated by RhoA/Rho-associated kinase|J03=Changes in intracellular calcium concentrations}} | |||
{{Family tree| | | | | | | | | | | | | | | |!| | | |!| | |`|-|v|-|'| | |!| | | | | | | | }} | |||
{{Family tree| | | | | | | | K01 | | | | | |!| |,|-|'| | | | K02 | | | |!| | | | | K03 | K01=Recruitement of fibrocytes in [[lungs]]|K02=Lock step mechanism of cyclic and contractile events|K03=[[T helper cell|T-helper cell type 2]] on site of injury}} | |||
{{Family tree| | | | | | | | |!| | | | | | |!| |!| | | | | | |!| | | | |!| | | | | |!| | }} | |||
{{Family tree| | | | | | | | L01 | | | | | | L02 | | | | | | L03 | | | |!| | | | | L04 | |L01=Upregulation of [[CXCR4|C-X-C chemokine receptor type 4 (CXCR4)]]<br>on [[fibrocytes]] and its ligand<br>CXCL12 (stromal cell-derived factor 1)|L02=Excess extracellular matrix production|L03=Exerting traction force|L04=[[Interleukin-13]]}} | |||
{{Family tree| | | | | | | | |!| | | | | | | |!|,|-|-|-|-|-|-|'| | | | |!| | | | | |!| | }} | |||
{{Family tree| | | | | | | | M01 | | | | | | M02 | | | | | | | | | | | |!| | | | | M03 | |M01=Migration of fibrocytes to the site of injury|M02=Tissue remodelling|M03=Alternate pathway activation of [[macrophages]]}} | |||
{{Family tree| | | | | | | | |!| | | | | | | |!| | | | | | | | | | | | |!| | | | | |!| | }} | |||
{{Family tree| | | | | | | | |`|-|-|-|-|-|-|.|!|,|-|-|-|-|-|-|-|-|-|-|-|'| | | | | |!| | }} | |||
{{Family tree| | | | | | | | | | | | | | | | N01 |-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|'| N01=Lung Fibrosis}} | |||
{{Family tree/end}} | |||
==References== | ==References== |
Revision as of 22:26, 7 March 2018
For the WikiPatient page for this topic, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Saarah T. Alkhairy, M.D.
Synonyms and keywords: Diffuse parenchymal lung disease; DPLD; ILD
Overview
Classification
Interstitial lung disease may be classified on the basis of lung response to tissue injury and include:[1]
- Lung response: Granulomatous
- Lung response: Alveolitis, interstitial inflammation, and fibrosis
Interstitial lung disease | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lung Response: Granulomatous | Lung Response: Alveolitis, Interstitial Inflammation, and Fibrosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Known | Idiopathic (Unknown) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hypersensitivity pneumonitis (organic dusts) | Inorganic dusts | Sarcoidosis | Lymphomatoid granulomatosis | Granulomatous vasculitides | Bronchocentric granulomatosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beryllium | Silica | Eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) | Granulomatosis with polyangiitis (Wegener) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Known cause | Idiopathic (Unknown) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug-induced pulmonary toxicity | Occupational and environmental exposure | Radiation-induced lung injury | Aspiration pneumonia | Smoking-related | Residual of acute respiratory distress syndrome | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhaled inorganic dust | Inhaled organic dusts | Inhaled agents other than inorganic or organic dusts | Desquamative interstitial pneumonia | Respiratory bronchiolitis–associated interstitial lung disease | Pulmonary Langerhans cell granulomatosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pulmonary alveolar proteinosis | Idiopathic interstitial pneumonias | Lymphocytic infiltrative disorders (lymphocytic interstitial pneumonitis associated with connective tissue disease) | Connective tissue diseases | Gastrointestinal or liver diseases | Inherited diseases | Graft-versus-host disease | Pulmonary hemorrhage syndromes | Eosinophilic pneumonias | Lymphangioleiomyomatosis | Amyloidosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Major idiopathic interstitial pneumonias | Rare idiopathic interstitial pneumonias | Unclassifiable idiopathic interstitial pneumonias | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Idiopathic pulmonary fibrosis • Idiopathic nonspecific interstitial pneumonia • Respiratory bronchiolitis-interstitial lung disease • Desquamative interstitial pneumonia • Cryptogenic organising pneumonia • Acute interstitial pneumonia | • Idiopathic lymphoid interstitial pneumonia • Idiopathic pleuroparenchymal fibroelastosis | • Systemic lupus erythematosus • Rheumatoid arthritis • Ankylosing spondylitis • Systemic sclerosis • Sjögren syndrome • Polymyositis • Dermatomyositis | • Crohn disease • Primary biliary cirrhosis • Chronic active hepatitis • Ulcerative colitis | • Tuberous sclerosis • Neurofibromatosis • Niemann-Pick disease • Gaucher disease • Hermansky-Pudlak syndrome | • Bone marrow transplantation • Solid organ transplantation | • Goodpasture syndrome • Idiopathic pulmonary hemosiderosis • Isolated pulmonary capillaritis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pathophysiology
Algorithm showing pathophysiology of Interstitial Lung Disease
Tissue injury in lungs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Parenchymal injury | Vascular injury | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mast cells in lungs in response to tissue injury | LPA6, LPA2, and LPA4 receptors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Decreased sFRP-1 (secreted frizzled-related protein 1) in fibroblasts | Secretes tryptase | Transforming growth factor-β (TGF-β) | Insulin-like growth factor (IGF) signalling | Reduced expression of angiogenic factors, vascular endothelial growth factor (VEGF) | Elevation of angiostatic factors, pigment epithelium-derived factor | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Wnt/β-catenin signalling pathway | PAR-2/protein kinase (PK)C-α/Raf-1/p44/42 signaling pathway | Upregulation of Egr-1 (early growth response protein 1) | IGF-binding protein 5 (IGFBP-5) | IGF-binding protein 3 (IGFBP-3) | Loss of endothelial barrier function | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dysregulation of repair in lung tissue and activation of fibroblasts | Regulates transforming growth factor-β (TGF-β) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Induction of syndecan-2 (SDC2) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Activation,proliferation, and migration of fibroblast to the site of injury | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fibroblasts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Altered PTEN (phosphatase and tensin homologue)/Akt axis | Acquire contractile stress fibres | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inactivates Fox (forkhead box) O3a | Protomyofibroblast, composed of cytoplasmic actins | Pleural mesothelial cells (PMCs) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Downregulation of caveolin-1 (cav-1) and Fas expression | De novo expression of α-smooth muscle actin (α-SMA) | TGF-β1-dependent mesothelial–mesenchymal transition | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fibroblast resistant to apoptosis | Myofibroblasts | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Different ranges of contractions mediated by RhoA/Rho-associated kinase | Changes in intracellular calcium concentrations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitement of fibrocytes in lungs | Lock step mechanism of cyclic and contractile events | T-helper cell type 2 on site of injury | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Upregulation of C-X-C chemokine receptor type 4 (CXCR4) on fibrocytes and its ligand CXCL12 (stromal cell-derived factor 1) | Excess extracellular matrix production | Exerting traction force | Interleukin-13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Migration of fibrocytes to the site of injury | Tissue remodelling | Alternate pathway activation of macrophages | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lung Fibrosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
Template:Respiratory pathology
de:Interstitielle Lungenerkrankung
fi:Keuhkoparenkyymisairaudet
- ↑ Kasper, Dennis (2015). "315: Interstitial Lung Diseases". In Talmadge, E. King, Jr. Harrison's principles of internal medicine. New York: McGraw Hill Education. ISBN 0071802150.